Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
Use of neuraminidase inhibitors for the treatment of pandemic and seasonal influenza especially for preventing severe disease
A recent paper from Thailand has reported how treatment with a neuraminidase inhibitor (oseltamivir) protected people with seasonal influenza against severe outcomes and death.
WHO updated evidence-based guidelines for use of influenza antivirals in the treatment of all influenza infections, Feb 2010
In February 2010 WHO published its Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses.
Differing effectiveness of the therapeutic and prophylactic use of antivirals and other measures for public health purposes during the 2009 influenza A(H1N1) pandemic
Two evaluations have recently been published looking at ‘micro’ and ‘macro’ attempts to contain the 2009 pandemic influenza in Singapore and the UK respectively with seeming differing outcomes.
Effectiveness of the therapeutic and prophylactic use of antivirals during seasonal influenza – experience in Hong Kong
This study assessed the effectiveness of within household oseltamivir treatment of a large number of people with seasonal influenza on reducing the duration of clinical illness and viral shedding in cases and the transmission to household contacts.
New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published
This evaluated patients admitted to hospital with laboratory-confirmed or clinically diagnosed influenza A H1N1pdm09 virus infection.
Pre-exposure prophylaxis for HIV in Europe
The use of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy, particularly among men who have sex with men (MSM) as well as other population groups at higher risk of HIV infection, has been receiving more and more attention during 2014. Preliminary results of clinical trials and research studies suggest that it could be an effective HIV prevention tool for Europe.
Pre-exposure prophylaxis to prevent HIV among MSM in Europe
The results of two clinical studies, PROUD and IPERGAY, suggests that the use of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) is an effective HIV prevention tool for Europe.